Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
A legfontosabb adatok
- Ki végzi
- Peking University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2/3. fázis
- Résztvevők
- 18 fő vett részt
- Kezdés
- 2021. dec. 24.
- Befejezés
- 2025. okt. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- HAIC
- TACE
- FOLFOX
- cTACE or DEB-TACE
- Donafenib
- A regiszteradat frissítve
- 2025. december 18.
- Miért állt le
- Difficult to enroll participants
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects must volunteer to participate in the study, signed informed consent, and were able to comply with the program requirements of visits and related procedures
- Age and gender: >18 years old and≤75 years old, both men and women
- All subjects must have Hepatocellular Carcinoma confirmed by pathological or clinical diagnosis
- Subjects are not suitable for radical resection or radical ablative therapy
- BCLC B based on Barcelona Clinic Liver Cancer staging system, and the lesions in the liver exceed up to 7 criteria, the number of tumors + the maximum diameter of tumors > 7
- Patients with viable and measurable target lesion per mRECIST
- Patients who are expected to live more than 3 months
- ECOG PS 0-1
- Child-Pugh class A
- Patients with laboratory values that meet the following criteria:; Hemoglobin≥90 g/L; Neutrophile granulocytes≥1.5×109/L; Platelet count≥75×109/L; Albumin≥30 g/L; Total serum bilirubin ≤ 2 times upper limits of normal; AST and ALT ≤ 5 times upper limits of normal; Serum creatinine ≤ 1.5 times upper limits of normal; Alkaline phosphatase ≤ 5 times upper limits of normal; Prothrombin time or international normalized ratio ≤ 1.5 times upper limits of normal, activated partial thromboplastin time (APTT) ≤ 1.5×ULN
Ki nem vehet részt
- Clinically significant cardiovascular disease, including, but not limited to, acute myocardial infarction, severe/unstable angina or prior coronary artery bypass surgery, congestive heart failure (NYHA >2), poorly controlled arrhythmias or arrhythmias requiring pacemaker therapy, hypertension not controlled by medication (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) within the past 6 months
- History of malignant tumor, excluding the following cases:; Malignant tumor that was curatively treated more than 5 years prior to study entry and has not recurred since then; Successful radical resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, preinvasive cervix carcinoma, and other preinvasive cancers
- Preexisting or history of hepatic encephalopathy, hepatorenal syndrome or liver transplantation
- History of surgical excision or ablation within 4 weeks of the start of treatment
- History of hepatic arterial infusion, more than twice TACE therapy, or history of TACE within 6 months of the start of treatment
- History of systemic therapy, including but not limited to chemotherapy, targeted therapy, immunotherapy
- History of thrombosis and/or embolism within 6 months of the start of treatment
- Clinically severe gastrointestinal bleeding within 6 months of the start of treatment or any life-threatening bleeding events within 3 months of the start of treatment
- Severe infections that are active or clinically poorly controlled
- If accompanied by acute or chronic active hepatitis B, unless taking antiviral drugs
- Other significant clinical and laboratory abnormalities, such as uncontrolled diabetes, chronic kidney disease, grade II or above peripheral neuropathy (CTCAE V5.0), and thyroid dysfunction, that may affect the safety evaluation
- Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma confirmed by histology or cytology
- Diffuse tumor lesion
- The lesions load in the liver exceeds 20, the number of tumors + the maximum diameter of tumors > 20
- Vascular invasion or extrahepatic metastasis
- Clinically uncontrolled ascites or pleural effusion
- Female patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant, and fertile female or male patient who is unwilling or unable to use effective contraception
- Multiple branches of hepatic artery with severe variation
- Any other subjects that the investigator considers ineligible
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with HAIC-TACE and donafenib compared to TACE plus donafenib in patients with BCLC B stage unresectable hepatocellular carcinoma (HCC) out of up-to-seven criteria.
A vizsgálat 2 csoportja
- HAIC-TACE-Dona GroupA vizsgált kezelés
200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with hepatic arterial infusion chemotherapy that consists of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. After 2-4 cycles of HAIC treatment, the sequential TACE therapy would be performed.
Kezelés: HAIC, TACE, FOLFOX, cTACE or DEB-TACE és Donafenib
- TACE-Dona GroupMár használt kezelés, összehasonlításként
200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with cTACE or DEB-TACE that mixed with EPI.
Kezelés: TACE, cTACE or DEB-TACE és Donafenib
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.
- A regiszteradat frissítve
- 2025. december 18.